NCT01051791View on ClinicalTrials.gov

Phase II Study of RAD001 Head and Neck Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 26, 2011

Study Completion Date

August 5, 2016

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Everolimus 10mg daily

RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.

Trial Locations (1)

15232

Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Julie E. Bauman, MD, MPH

OTHER